PRLR drug-target Mendelian randomization for endometriosis
This drug-target Mendelian randomization study found that genetically predicted higher prolactin receptor expression increases endometriosis risk, a finding supported by colocalization and replication across multiple cohorts.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
This study employs cis-expression quantitative trait locus Mendelian randomization to investigate the causal relationship between prolactin receptor expression and endometriosis risk. The researchers utilized summary statistics from large-scale genome-wide association studies, including data from eQTLGen, FinnGen, and the Rahmioglu 2023 endometriosis GWAS, alongside colocalization analyses to confirm shared genetic signals. The findings provide genetic evidence supporting the repurposing of prolactin receptor inhibition as a potential therapeutic strategy for treating endometriosis. This paper is centrally about endometriosis — specifically evaluating the genetic causality of the prolactin receptor pathway in disease pathogenesis.
Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works
Abstract
Full text
650 characters
· extracted from
oa-html
· click to expand
Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.
My notes (saved in your browser only)
Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.
Source provenance
- openalex
- last seen: 2026-09-30T06:08:52.026869+00:00